Plain-English translation of NCT06826092 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether metformin—a medication commonly used to treat diabetes—can help improve treatment outcomes when added to standard chemotherapy for advanced colorectal cancer. Half of participants will receive chemotherapy alone, while the other half will take metformin along with the same chemotherapy regimen. Researchers want to see if the medication helps people live longer without their cancer getting worse.
Some early research suggests that metformin may have anti-cancer properties and could potentially boost the effectiveness of chemotherapy. This trial will help doctors understand whether adding this affordable, well-tolerated medication to standard treatment can make a real difference for patients with advanced colorectal cancer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll receive the standard FOLFIRI chemotherapy regimen that your doctor has already planned for you. Depending on which group you're assigned to, you may also take metformin (a pill) three times daily. You'll have regular blood tests and clinic visits to monitor how you're responding to treatment and to watch for any side effects, just as you would with standard cancer care alone. The study will track how long you survive and how well your cancer responds to treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Taiwan
Phase
Testing effectiveness
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Enrollment target
~110 participants
Started
October 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years – 90 Years
Last updated on clinicaltrials.gov in February 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.